Noval madcam antibodies

Abstract

The invention provides new, improved anti-MAdCAM antibodies. Uses of these antibodies in medicine are also included, in particular for the treatment of inflammatory conditions such as inflammatory bowel disease.

1 - 4 . (canceled) 
     
     
         5 . A method for treating inflammatory disease in a patient comprising administering a therapeutically effective amount of a monoclonal antibody that specifically binds MAdCAM, or antigen-binding portion thereof, selected from the group consisting of:
 (a) an antibody comprising the variable region of the heavy chain of 6.22.2-mod_V (SEQ ID NO: 2) with or without signal sequence;   (b) an antibody comprising the variable region of the light chain of 6.34.2-mod_SSQ, 6.34.2-mod_QT, or 6.34.2-mod_SSQ,QT (SEQ ID NOs: 8, 10, 12) with or without signal sequence;   (c) an antibody comprising the variable region of the light chain of 6.67.1-mod_Y, 6.67.1-mod_TΔP, or 6.67.1-mod_Y,TΔP (SEQ ID NOs: 16, 18, 20) with or without signal sequence;   (d) an antibody comprising the variable region of the heavy chain of 6.77.1-mod_AS (SEQ ID NO: 22) with or without signal sequence;   (e) an antibody comprising the variable region of the heavy chain of 7.16.6 (SEQ ID NO: 26), or 7.16.6_L (SEQ ID NO: 28) with or without signal sequence; or   (f) an antibody comprising the variable region of the light chain of 7.16.6_V, 7.16.6_S, or 7.16.6_VS (SEQ ID NOs: 30, 32, 34) with or without signal sequence;   (g) an antibody comprising the variable region of the light chain of 7.16.6_V, 7.16.6_S, or 7.16.6_VS (SEQ ID NOs: 30, 32, 34) with or without signal sequences and the variable region of the heavy chain of 7.16.6 (SEQ ID NO: 26) or 7.16.6_L (SEQ ID NO: 28) with or without signal sequence;   (h) an antibody comprising the variable region of the heavy chain of 9.8.2_ΔRGAYH,D (SEQ ID NO: 36) with or without signal sequence; and   (i) an antibody comprising the variable region of the light chain of 9.8.2-mod (SEQ ID NO: 38) with or without signal sequence.   
     
     
         6 . The method of  claim 5 , wherein the inflammatory disease is inflammatory bowel disease, liver fibrosis, graft versus host disease, or uveitis. 
     
     
         7 . The method of  claim 6 , wherein the inflammatory bowel disease is Crohn's disease or ulcerative colitis. 
     
     
         8 . The method of  claim 5 , wherein the heavy chain C-terminal lysine of the antibody or portion thereof is cleaved. 
     
     
         9 . The method of  claim 5 , wherein the antibody or portion thereof comprises:(a) the variable region of the amino acid sequence set forth in SEQ ID NOs: 30, 32, or 34, without the signal sequence; and (b) the variable region of the amino acid sequence set forth in SEQ ID NO: 26 or 28, without the signal sequence. 
     
     
         10 . The method of  claim 9 , wherein the antibody comprises:(a) the light chain amino acid sequence set forth in SEQ ID NO: 30, 32, or 34, without the signal sequence; and (b) the heavy chain amino acid sequence set forth in SEQ ID NO: 26 or 28, without the signal sequence. 
     
     
         11 - 14 . (canceled)